Literature DB >> 16601919

Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease.

T Majima1, Y Komatsu, K Doi, C Takagi, M Shigemoto, A Fukao, T Morimoto, J Corners, K Nakao.   

Abstract

INTRODUCTION: Although it has been established that hyperthyroidism leads to reduced bone mineral density (BMD), with accelerated bone turnover promoting bone resorption in female patients, there is a dearth of data for male patients with hyperthyroidism. This study evaluated BMD and bone metabolism in male patients with Graves' disease.
METHODS: The study included 56 Japanese male patients with newly diagnosed Graves' disease and 34 normal Japanese male control subjects of similar age and body mass index. We used dual energy x-ray absorptiometry to measure BMD at sites with different cortical/cancellous bone ratios (lumbar spine, femoral neck, and distal radius).
RESULTS: At the lumbar spine and the distal radius, BMD and T-scores were significantly lower for patients than for controls. At the femoral neck, on the other hand, the same values were relatively, but not significantly, lower in patients than in controls. However, Z-scores at all three sites were significantly lower for patients than for controls. The Z -score at the distal radius of patients was significantly lower than that at their lumbar spine and femoral neck. In addition, Z-score at the distal radius correlated negatively with age, free thyroxine, thyroid stimulating hormone receptor antibodies, thyroid stimulating antibody, and urinary N-terminal telopeptide of type I collagen normalized by creatinine.
CONCLUSIONS: These results indicate a high prevalence of cortical bone loss in male patients with Graves' disease, especially elderly patients. We conclude that BMD measurement is crucial in all Graves' disease patients regardless of their gender and that the radial BMD as well as BMD at the lumbar spine and femoral neck should be monitored to effectively prevent bone loss and subsequent fracture.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601919     DOI: 10.1007/s00198-006-0091-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  38 in total

1.  Osteoporosis treatment in elderly hyperthyroid male patients.

Authors:  M R Fittipaldi; F Fonderico; G Vitale; A Ciccarelli; G A Lupoli; T Cascella; A Panico; G Lupoli
Journal:  J Endocrinol Invest       Date:  2002       Impact factor: 4.256

2.  Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism.

Authors:  M S Lee; S Y Kim; M C Lee; B Y Cho; H K Lee; C S Koh; H K Min
Journal:  J Clin Endocrinol Metab       Date:  1990-03       Impact factor: 5.958

3.  Fracture risk in patients treated for hyperthyroidism.

Authors:  P Vestergaard; L Rejnmark; J Weeke; L Mosekilde
Journal:  Thyroid       Date:  2000-04       Impact factor: 6.568

4.  Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin.

Authors:  Tadashi Morimura; Katsuhiko Tsunekawa; Takayuki Kasahara; Koji Seki; Takayuki Ogiwara; Masatomo Mori; Masami Murakami
Journal:  Endocrinology       Date:  2005-01-13       Impact factor: 4.736

5.  Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development.

Authors:  S Mora; P Pitukcheewanont; F R Kaufman; J C Nelson; V Gilsanz
Journal:  J Bone Miner Res       Date:  1999-10       Impact factor: 6.741

6.  Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves' disease.

Authors:  N Lucidarme; J C Ruiz; P Czernichow; J Léger
Journal:  J Pediatr       Date:  2000-07       Impact factor: 4.406

7.  Relationships existing between the serum cytokine levels and bone mineral density in women in the premenopausal period affected by Graves' disease with subclinical hyperthyroidism.

Authors:  Betül Ugur-Altun; Armagan Altun; Ender Arikan; Sibel Guldiken; Armagan Tugrul
Journal:  Endocr Res       Date:  2003-11       Impact factor: 1.720

8.  Bone mineral density in patients with hyperthyroidism measured by dual energy X-ray absorptiometry.

Authors:  M Wakasugi; R Wakao; M Tawata; N Gan; K Koizumi; T Onaya
Journal:  Clin Endocrinol (Oxf)       Date:  1993-03       Impact factor: 3.478

9.  Effect of hyperthyroidism and its treatment on bone mineral content.

Authors:  S H Toh; B C Claunch; P H Brown
Journal:  Arch Intern Med       Date:  1985-05

10.  Peripheral bone density in women with untreated multinodular goitre.

Authors:  A H Mudde; F J Reijnders; A C Kruseman
Journal:  Clin Endocrinol (Oxf)       Date:  1992-07       Impact factor: 3.478

View more
  5 in total

1.  Association between calcaneus quantitative ultrasound (QUS) parameters and thyroid status in middle-aged and elderly Chinese men with euthyroidism: a population-based cross-sectional study.

Authors:  Yun Shi; Min Sun; Zhixiao Wang; Qi Fu; Mengdie Cao; Zhenxin Zhu; Chuchen Meng; Jia Mao; Yu Duan; Wei Tang; Xiaoping Huang; Jieli Lu; Yufang Bi; Guang Ning; Wei He; Tao Yang
Journal:  Endocrine       Date:  2014-01-24       Impact factor: 3.633

2.  Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?

Authors:  Tina Z Belsing; Charlotte Tofteng; Bente L Langdahl; Peder Charles; Ulla Feldt-Rasmussen
Journal:  Nutr Metab (Lond)       Date:  2010-09-01       Impact factor: 4.169

3.  Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves' disease.

Authors:  Monica A Ercolano; Monica L Drnovsek; Maria C Silva Croome; Monica Moos; Ana M Fuentes; Fanny Viale; Ulla Feldt-Rasmussen; Alicia T Gauna
Journal:  Thyroid Res       Date:  2013-09-11

4.  Choroidal Thickness in Relation to Bone Mineral Density with Swept-Source Optical Coherence Tomography.

Authors:  Lin Jiang; Yiwen Qian; Qingjian Li; Jing Jiang; Yu Zhang; Xin Che; Zhiliang Wang
Journal:  J Ophthalmol       Date:  2021-09-25       Impact factor: 1.909

5.  Dyslipidemia and serum mineral profiles in patients with thyroid disorders.

Authors:  Abdelgayoum A Abdel-Gayoum
Journal:  Saudi Med J       Date:  2014-12       Impact factor: 1.484

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.